公开(公告)号：US20200247747A1

公开(公告)日：2020-08-06

申请号：US16777273

申请日：2020-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi Hattori ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Norihito Tokunaga ,  Alexander Martin Pawliczek ,  Tsuneo Oda ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto

IPC: C07D207/14 ,  C07D417/06 ,  C07D407/08

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10428023B2

公开(公告)日：2019-10-01

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D405/06 ,  C07D211/36

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11440883B2

公开(公告)日：2022-09-13

申请号：US16811426

申请日：2020-03-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  C07D211/36 ,  C07D405/06 ,  A61P25/26 ,  C07D409/10 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11319286B2

公开(公告)日：2022-05-03

申请号：US16635408

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Yuichi Kajita ,  Satoshi Mikami ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Masaki Daini ,  Masaki Ogino ,  Kohei Takeuchi ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D207/14 ,  C07D401/14 ,  C07D403/06 ,  A61P25/28

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10435399B2

公开(公告)日：2019-10-08

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro Ito ,  Hideyuki Sugiyama ,  Osamu Kubo ,  Fumiaki Kikuchi ,  Takeshi Yasui ,  Keiko Kakegawa ,  Zenichi Ikeda ,  Tohru Miyazaki ,  Yasuyoshi Arikawa ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Akinori Toita ,  Takuto Kojima ,  Yasutomi Asano ,  Ayumu Sato ,  Hironobu Maezaki ,  Shinobu Sasaki ,  Hironori Kokubo ,  Misaki Homma ,  Minoru Sasaki ,  Yasuhiro Imaeda

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D487/04 ,  A61P25/28 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US12091410B2

公开(公告)日：2024-09-17

申请号：US17413473

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Norihito Tokunaga ,  Tsuneo Oda ,  Tohru Miyazaki ,  Dilhumar Uyghur ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto ,  Koichiro Fukuda ,  Yasuhisa Kohara ,  Rei Okamoto ,  Taiichi Ohra ,  Naoki Miyamoto ,  Yoshito Terao ,  Masanori Kawasaki

IPC: C07D471/04 ,  C07D215/38 ,  C07D231/56 ,  C07D277/64 ,  C07D401/14

CPC classification number: C07D471/04 ,  C07D215/38 ,  C07D231/56 ,  C07D277/64 ,  C07D401/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US12071434B2

公开(公告)日：2024-08-27

申请号：US17413469

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Norihito Tokunaga ,  Tsuneo Oda ,  Tohru Miyazaki ,  Dilhumar Uyghur ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto ,  Koichiro Fukuda ,  Yasuhisa Kohara ,  Rei Okamoto ,  Taiichi Ohra ,  Naoki Miyamoto ,  Jun Chiba ,  Yoshito Terao ,  Masanori Kawasaki

IPC: C07D455/02 ,  A61P25/26 ,  C07D217/24 ,  C07D237/32 ,  C07D239/90 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04

CPC classification number: C07D455/02 ,  A61P25/26 ,  C07D217/24 ,  C07D237/32 ,  C07D239/90 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04 ,  C07B2200/05

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11655241B2

公开(公告)日：2023-05-23

申请号：US16973320

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tsuneo Oda ,  Yoshiteru Ito ,  Tohru Miyazaki ,  Kohei Takeuchi ,  Norihito Tokunaga ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura ,  Yuichi Kajita ,  Yuhei Miyanohana ,  Takahiro Sugimoto ,  Tatsuki Koike ,  Dilhumar Uyghur

IPC: C07D405/12 ,  C07D207/14 ,  C07D211/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D405/14 ,  C07D417/06 ,  C07D417/14

CPC classification number: C07D405/12 ,  C07D207/14 ,  C07D211/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D405/14 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10584097B2

公开(公告)日：2020-03-10

申请号：US16577449

申请日：2019-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  C07D405/06 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D211/36 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US12084436B2

公开(公告)日：2024-09-10

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro Ito ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Hideyuki Sugiyama ,  Tohru Miyazaki ,  Yasuyoshi Arikawa ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Osamu Kubo ,  Akinori Toita ,  Takuto Kojima ,  Fumiaki Kikuchi ,  Minoru Sasaki ,  Misaki Homma ,  Yasuhiro Imaeda ,  Hironobu Maezaki ,  Shiinobu Sasaki ,  Ayumu Sato ,  Hirotaka Kamitani ,  Yasutomi Asano ,  Hironori Kokubo ,  Masato Yoshikawa

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.